The overall incidence of cancer for our study cohort was 1·9%, which is similar to the 2·4% reported in the BRCA1 and BRCA2 cohort of IMPACT and lower than the 4·3% of men diagnosed in the first screening round of the ERPSC.31 This evidence concerns the gene BRCA2 and cancer.